TORNTPHARM Q2 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,660 Cr
verified against source
Revenue YoY
16%
reported change
EBITDA
₹825 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered a strong Q2 FY24 with 16% YoY revenue growth to INR 2,660 crores and 31% EBITDA margin (up 250bps YoY), driven by robust branded generics performance across markets. India business posted 18% growth (12% organic) with market outperformance vs. 4% IPM growth; the Curatio integration is delivering 14% higher EBITDA margins than pre-acquisition. Brazil grew 23% in BRL terms with 7-8pp outperformance vs. market; Germany rose 21% on tender wins. U.S. declined 15% to INR 248 crores ($30M) due to low-margin product exits and supply issues, but Dahej received EIR clearance enabling new launches. The company capitalized its oral oncology facility in July and launched sorafenib with double-digit market share. Net debt/EBITDA is at 1.16x, targeting sub-1x by March 2024. Management sees sustainable 75% gross margins, expects U.S. to stabilize at $30-35M quarterly pending new approvals, and flagged market concerns around trade generics structurally pressuring India growth—but believes risk is overestimated. Field force and marketing investments are one-time cost builds stabilizing in FY24.
Colored figures show movement against the previous available record.
Guidance to track
- Sequential stabilization expected as new product approvals from Dahej and Indrad plants begin flowing through. Dahej EIR received enabling new launches. Price erosion running mid-single to high-single digit annually.
- Portfolio optimization in U.S. and cost efficiencies are driving structural improvement. No one-off impacts in Q2. No immediate headroom for further expansion in next two quarters.
- AIOCD 4% market growth is understated; real market is ~7-8%. Acute therapies reviving; gastro demand improving sequentially. Torrent delta vs. market expected to remain similar for rest of FY24 and FY25.
- Currently at 1.16x leverage. Cash generation from strong EBITDA (31% margin) and working capital management will reduce debt. March 2024 target achievable.
Risks flagged
- U.S. declined 15% (18% in constant currency) with $30M revenue vs. $36M year-ago. Recovery to $200M+ annualized target hinges on Dahej and Indrad plant inspections/approvals—a regulatory timing risk. Management declined to quantify one-off impacts from product exits.
- While management argues 4% AIOCD growth understates real market (7-8%), analyst Saion Mukherjee challenged whether trade generics, Jan Aushadhi, and private labels represent a structural shift dragging growth from historical 10% to 7-8%. Management called this risk 'overestimated' but acknowledged ~0.5% IPM impact possible.
- Analyst raised government initiatives to push doctors toward writing generic names. Management noted quality infrastructure gaps exist but predicted branded generics will persist in hybrid system. No specific mitigation announced for potential policy-driven market share erosion.
- Multiple analysts probed capital allocation and M&A priorities; CFO deflected, declining to comment on valuation targets, deal size philosophy, or whether management seeks to be top-5 vs. top-10 Indian pharma. Comfortable starting leverage of 3x (declining to 1.5-2x) stated but no specific acquisition pipeline disclosed.
Key quotes
- The risk of trade generics cannibalizing branded generics is overestimated right now. In our view, the real market growth would be closer to around 7% or 8% this quarter.
- We capitalized in the month of July. So all the costs pertaining to manufacturing is already captured as part of the gross margin, I would say or the EBITDA margin. So nothing incremental month-on-month, going forward from here.
- In the U.S., we're just waiting for two things. One is for new molecules and new products to get approved from the Dahej... And as you know, Indrad, we've completed all the formalities. We're just waiting for inspection.
Research modules